Maren Hermanns-Clausen1, Dieter Müller2, Josephine Kithinji1, Verena Angerer3,4, Florian Franz3,4, Florian Eyer5, Hartmud Neurath2, Gesine Liebetrau6, Volker Auwärter3. 1. a Poisons Information Center, Department of General Pediatrics , Adolescent Medicine and Neonatology, Center for Pediatrics, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg , Germany. 2. b GIZ-Nord Poisons Center, University Hospital Göttingen , Göttingen , Germany. 3. c Institute of Forensic Medicine, Forensic Toxicology , Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg , Germany. 4. d Hermann Staudinger Graduate School , University of Freiburg , Freiburg , Germany. 5. e Department of Clinical Toxicology, Klinikum rechts der Isar , Technical University of Munich , Munich , Germany. 6. f Poisons Informations Center , Erfurt , Germany.
Abstract
INTRODUCTION: In 2014, the "European Monitoring Centre for Drugs and Drug Addiction" (EMCDDA) reported on 30 novel synthetic cannabinoids (SCs). Among these were indole- and indazole-based valine derivatives with a cyclohexylmethyl side chain (e.g., AB-CHMINACA and MDMB-CHMICA), which represent a new class of SCs. METHODS: A prospective observational study of patients treated in emergency departments (EDs) after the intake of SCs was conducted. Clinical and laboratory data were combined and reported to a poison control centre. Serum and/or urine samples of ED patients were analyzed using LC-MS/MS. RESULTS: Forty four patients (39 male, five female, 12-48 years) were included. AB-CHMINACA (MDMB-CHMICA) was identified in 20 (19) serum samples, and in 21 (25) urine samples, respectively. In 19 of the cases, more than one SC was present. Other psychoactive substances (mainly amfetamines) were identified in seven cases, but in five out of these in urine samples only. Based on the Poison Severity Score, severity of poisoning was minor (4), moderate (31) or severe (9). Most frequently reported neuropsychiatric symptoms were CNS-depression (n = 21, 61%), disorientation (n = 20, 45%), generalized seizures (n = 12, 27%), combativeness (n = 8, 18%) and extreme agitation (n = 7, 16%). Duration of symptoms lasting 24 hours or longer occurred in 15 cases (34%). DISCUSSION: The prevalence of certain neuropsychiatric symptoms was higher in our study than in former reports after the intake of SCs of the aminoalkylindole-type (first generation) SCs. In addition, severe poisoning and duration of symptoms were also higher. CONCLUSIONS: In this study, the valine derivative AB-CHMINACA and the tert-leucine derivative MDMB-CHMICA ("third generation of SCs") seem to be associated with more severe clinical toxicity than was previously reported in patients exposed to earlier generation SCs such as JWH-018. However, this observation needs to be confirmed with a larger cohort of patients with analytically confirmed abuse of third generation SCs. The rapid turnover of SCs on the drug market together with the occurrence of SCs such as AB-CHMINACA and MDMB-CHMICA is alarming, especially because of the unexpectedly high frequency of neuropsychiatric symptoms.
INTRODUCTION: In 2014, the "European Monitoring Centre for Drugs and Drug Addiction" (EMCDDA) reported on 30 novel synthetic cannabinoids (SCs). Among these were indole- and indazole-based valine derivatives with a cyclohexylmethyl side chain (e.g., AB-CHMINACA and MDMB-CHMICA), which represent a new class of SCs. METHODS: A prospective observational study of patients treated in emergency departments (EDs) after the intake of SCs was conducted. Clinical and laboratory data were combined and reported to a poison control centre. Serum and/or urine samples of ED patients were analyzed using LC-MS/MS. RESULTS: Forty four patients (39 male, five female, 12-48 years) were included. AB-CHMINACA (MDMB-CHMICA) was identified in 20 (19) serum samples, and in 21 (25) urine samples, respectively. In 19 of the cases, more than one SC was present. Other psychoactive substances (mainly amfetamines) were identified in seven cases, but in five out of these in urine samples only. Based on the Poison Severity Score, severity of poisoning was minor (4), moderate (31) or severe (9). Most frequently reported neuropsychiatric symptoms were CNS-depression (n = 21, 61%), disorientation (n = 20, 45%), generalized seizures (n = 12, 27%), combativeness (n = 8, 18%) and extreme agitation (n = 7, 16%). Duration of symptoms lasting 24 hours or longer occurred in 15 cases (34%). DISCUSSION: The prevalence of certain neuropsychiatric symptoms was higher in our study than in former reports after the intake of SCs of the aminoalkylindole-type (first generation) SCs. In addition, severe poisoning and duration of symptoms were also higher. CONCLUSIONS: In this study, the valine derivative AB-CHMINACA and the tert-leucine derivative MDMB-CHMICA ("third generation of SCs") seem to be associated with more severe clinical toxicity than was previously reported in patients exposed to earlier generation SCs such as JWH-018. However, this observation needs to be confirmed with a larger cohort of patients with analytically confirmed abuse of third generation SCs. The rapid turnover of SCs on the drug market together with the occurrence of SCs such as AB-CHMINACA and MDMB-CHMICA is alarming, especially because of the unexpectedly high frequency of neuropsychiatric symptoms.
Entities:
Keywords:
CNS/psychological; Novel psychoactive substances; human clinical data; synthetic cannabis
Authors: Sarah Ann R Anderson; Anna M Oprescu; Diane Calello; Andrew Monte; Peter S Dayan; Yasmin L Hurd; Alex F Manini Journal: Pediatrics Date: 2019-07-08 Impact factor: 7.124
Authors: Arianna Giorgetti; Francesco Paolo Busardò; Roberta Tittarelli; Volker Auwärter; Raffaele Giorgetti Journal: Front Psychiatry Date: 2020-05-25 Impact factor: 4.157
Authors: Richard C Kevin; Lyndsey Anderson; Iain S McGregor; Rochelle Boyd; Jamie J Manning; Michelle Glass; Mark Connor; Samuel D Banister Journal: Front Pharmacol Date: 2019-05-29 Impact factor: 5.810
Authors: Eric Sparkes; Rochelle Boyd; Shuli Chen; Jack W Markham; Jia Lin Luo; Tahira Foyzun; Humayra Zaman; Charlotte Fletcher; Ross Ellison; Iain S McGregor; Marina J Santiago; Felcia Lai; Roy R Gerona; Mark Connor; David E Hibbs; Elizabeth A Cairns; Michelle Glass; Adam Ametovski; Samuel D Banister Journal: Front Psychiatry Date: 2022-09-28 Impact factor: 5.435